Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

NCT03375320 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

298

Enrollment

NIH

Sponsor class

Conditions

Functioning Pancreatic Neuroendocrine Tumor
Intermediate Grade Lung Neuroendocrine Neoplasm
Locally Advanced Digestive System Neuroendocrine Neoplasm
Locally Advanced Digestive System Neuroendocrine Tumor G1
Locally Advanced Lung Neuroendocrine Neoplasm
Locally Advanced Pancreatic Neuroendocrine Tumor
Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm
Low Grade Lung Neuroendocrine Neoplasm
Lung Neuroendocrine Tumor
Lung Neuroendocrine Tumor G2
Metastatic Digestive System Neuroendocrine Neoplasm
Metastatic Digestive System Neuroendocrine Tumor G1
Metastatic Lung Neuroendocrine Neoplasm
Metastatic Lung Neuroendocrine Tumor
Metastatic Pancreatic Neuroendocrine Neoplasm
Metastatic Pancreatic Neuroendocrine Tumor
Metastatic Thymus Neuroendocrine Neoplasm
Neuroendocrine Neoplasm
Neuroendocrine Tumor
Neuroendocrine Tumor G2
Non-Functioning Pancreatic Neuroendocrine Tumor
Pancreatic Serotonin-Producing Neuroendocrine Tumor
Thymus Neuroendocrine Tumor
Unresectable Digestive System Neuroendocrine Neoplasm
Unresectable Digestive System Neuroendocrine Tumor G1
Unresectable Lung Neuroendocrine Neoplasm
Unresectable Pancreatic Neuroendocrine Neoplasm
Unresectable Thymus Neuroendocrine Neoplasm

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Cabozantinib S-malate
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging
OTHER: Placebo Administration
OTHER: Quality-of-Life Assessment
PROCEDURE: X-Ray Imaging

Sponsor

National Cancer Institute (NCI)